Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30235634 | 1.00 | CA2 (0.55) | CA2CA4MMEGAAMAPT | |
| SCHEMBL9957315 | 0.91 | GNPAT (0.50) | CA2CA4MMEGAAMAPT | |
| SCHEMBL14177314 | 0.84 | FOLH1 (0.60) | CA2CA4MMEGAAMAPT | |
| SCHEMBL6240482 | 0.80 | ECE1 (0.53) | CA2CA4MAPTCA1FOLH1 | |
| SCHEMBL4572564 | 0.80 | CA2 (0.62) | CA2CA4MMEGAAMAPT | |
| SCHEMBL13674348 | 0.80 | CA2 (0.62) | CA2CA4MMEGAAMAPT | |
| SCHEMBL13084159 | 0.80 | ECE1 (0.53) | CA2CA4MAPTCA1FOLH1 | |
| SCHEMBL21494995 | 0.80 | CA2 (0.52) | CA2CA4MMEGAAMAPT | |
| SCHEMBL22902276 | 0.80 | CA2 (0.52) | CA2CA4MMEGAAMAPT | |
| N-Acetylaspartic Acid SCHEMBL37946 | 0.80 | MAPT (0.61) | CA2CA4MMEGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110652595-B | Poly leucine-poly aspartic acid segmented copolymer stereo composite drug-loaded micelle and preparation method thereof | 南通大学附属医院 | 2022-11-29 | — | — | CN | claimed |
| CN-119855583-A | Composition for cosmetic treatment of keratin fibres | 碧昂赛恩斯公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119546274-A | Composition comprising a peroxo salt, a specific content of fatty substances, an amino acid type compound and a specific (poly) carboxylic acid | 莱雅公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119486706-A | Composition comprising a peroxo salt, a hydrocarbon with a melting point of 85 ℃ or higher and at least 10% fatty substances | 莱雅公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119421695-A | Composition comprising a peroxo salt, a hydrocarbon having a melting point of more than 25 ℃, and an amino acid type compound | 莱雅公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119421694-A | Composition comprising a peroxo salt, an associative polymer, a non-associative polysaccharide and a hydrocarbon having a melting point greater than 25 DEG C | 莱雅公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4423169-A1 | IMPROVED BRANCHED WETTING AGENTS FOR ENHANCED TREATMENT OF DROUGHT FIELD CONDITIONS | Milliken & Company (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118267455-A | Formulations of glucagon-like peptide 2 (GLP-2) analogs | 西兰制药公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3509619-B1 | PEPTIDES AND PEPTIDE CONJUGATES FOR TREATING MENTAL DISORDERS | UNIV KYOTO (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20240199710-A1 | BIOACTIVE POLYPEPTIDES AND METHODS RELATED THERETO | LINCOLN UNIVERSITY (NZ) | 2024-06-20 | — | — | US | disclosed |
| EP-0926159-A2 | Glucagon-like peptide-1 crystals | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999030731-A1 | GLUCAGON-LIKE PEPTIDE-1 CRYSTALS | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999029336-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5808001-A | POLYPEPTIDE | INCYTE PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998019698-A1 | USE OF GLP-1 ANALOGS AND DERIVATIVES ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY | ELI LILLY AND COMPANY (US) | 1998-05-14 | — | — | WO | disclosed |
| EP-0832251-A1 | HUMAN ICE HOMOLOG | INCYTE PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998008531-A1 | USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998008873-A1 | USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| US-5654146-A | INTERLEUKIN CONVERTING ENZYME; ISOLATED AND PURIFIED POLYPEPTIDE | INCYTE PHARMACEUTICALS, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996038569-A1 | HUMAN ICE HOMOLOG | INCYTE PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |